Compare VFS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | KRYS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Vietnam | United States |
| Employees | 17823 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | VFS | KRYS |
|---|---|---|
| Price | $2.97 | $248.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.83 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 306.9K | 191.6K |
| Earning Date | 03-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | N/A | $40.88 |
| Revenue Next Year | $2,810,877.80 | $35.16 |
| P/E Ratio | ★ N/A | $36.29 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $2.56 | $123.03 |
| 52 Week High | $3.82 | $298.30 |
| Indicator | VFS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 44.26 |
| Support Level | N/A | $248.73 |
| Resistance Level | $3.36 | $297.14 |
| Average True Range (ATR) | 0.08 | 8.56 |
| MACD | -0.01 | -0.38 |
| Stochastic Oscillator | 51.35 | 34.76 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.